However, the efficacy of these agents in reducing cardiovascular endpoints among patients living with obesity or overweight is unclear.Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing GLP-1 RAs versus placebo in patients with obesity or ...
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) constitute a class of drugs for the treatment of type 2 diabetes, and currently, six different GLP-1RAs are approved. Besides improving glycemic control, the GLP-1RAs have other beneficial effects such as weight loss and a low ...
some of them have shown limited or probably even unfavorable effects on the cardiovascular system and overall mortality. Recently, incretin-based therapies (GLP-1 receptor agonists and DPP-IV inhibitors) have been introduced in the treatment of T2DM. Beside the effects of GLP-1 on insulin secretio...
He also talked about how the findings of this study might influence future research or development of GLP-1 analogs for neurological conditions. Furthermore, Edison spoke about the implications of using semaglutide, an oral GLP-1 analog, in the treatment of AD. Click here for more coverage of...
The results suggest that the cardiovascular benefits induced by GLP-1R are mediated via suppressed expression of two miRNAs: miR-203a-3p and miR-429. 展开 关键词: REVERSE transcriptase polymerase chain reaction GLUCAGON-like peptide-1 receptor LDL cholesterol TYPE 2 diabetes HDL cholesterol ...
L-proline plays important roles in protein synthesis and structure, metabolism (particularly the synthesis of arginine, polyamines, and glutamate via pyrroline-5-carboxylate), and nutrition, as well as wound healing, antioxidative reactions, and immune responses. Stronger Muscle Health L-proline supple...
GLP-1 receptor agonists are approved for the treatment of type 2 diabetes, and more recently for obesity treatment. The glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced by intestinal cells, which is involved in insulin secretion and glucagon suppression. This hormone ...
This Sidebar video considers the role of DTx in delivering remote care to patients with cancer. Find out more about Sidekick's plans to work on digital therapeutics to manage side effects in chemotherapy.
“This is the first study to show a clear benefit of GLP-1 receptor agonists on kidney failure or end-stage kidney disease, suggesting they have a key role in kidney-protective and heart-protective treatment for patients with common medical conditions like type 2 diabetes, overweight o...
“These studies reinforce the potential of GLP-1-based therapies not only to aid in weight loss but also to transform cardiac health, offering hope for patients living with obesity andcardiovascular disease,” said Harlan M. Krumholz, MD, SM, editor-in-chief ofJACCand the Harold H. Hines Jr...